10-KPeriod: FY2022

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2022

Filed February 10, 2023For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) filed its 2022 10-K report, detailing its continued growth in a dynamic global healthcare landscape. The company saw an 18% increase in da Vinci procedures, reaching approximately 1.875 million, alongside a substantial 218% rise in Ion system procedures to 23,500. This procedural growth drove a 13% increase in instruments and accessories revenue, highlighting the recurring revenue model's strength. However, systems revenue saw a slight 1% decrease, attributed to macroeconomic pressures, particularly in the U.S., which impacted hospital capital spending, and a 6% decline in da Vinci system placements. Despite these system placement challenges, the overall installed base of da Vinci systems grew by 12% to 7,544 units, indicating ongoing market penetration and adoption. The company's financial performance in 2022 showed total revenue growth of 9% to $6.2 billion, though operating income decreased by 13% to $1.58 billion, impacted by increased investments in R&D and SG&A expenses, including higher headcount and infrastructure costs. The gross profit margin also saw a slight decrease to 67.4% from 69.3% in the prior year, influenced by rising freight and material costs and unfavorable foreign currency impacts. Looking ahead, Intuitive Surgical faces ongoing risks related to macroeconomic conditions, supply chain constraints, and potential regulatory changes. The company is actively managing these challenges by focusing on innovation, expanding its product portfolio, and investing in its global infrastructure to support long-term growth and its mission of advancing minimally invasive care.

Financial Highlights

47 data points
Beta

Revenue

$6.22B

67.4% Gross Margin

Net Income

$1.32B

21.3% Net Margin

EPS (Diluted)

$3.65

Total Assets

$12.97B

Cash & Equivalents

$1.60B

Free Cash Flow

$1.49B

Financial Statements
Beta
Revenue$6.22B
Cost of Revenue$2.03B
Gross Profit$4.20B
R&D Expenses$879.00M
SG&A Expenses$1.74B
Operating Expenses$2.62B
Operating Income$1.58B
Net Income$1.32B
EPS (Basic)$3.72
EPS (Diluted)$3.65
Shares Outstanding (Basic)355.70M
Shares Outstanding (Diluted)362.00M

Key Highlights

  • 1Total revenue increased 9% year-over-year to $6.2 billion in 2022.
  • 2da Vinci procedure volume grew 18% to approximately 1.875 million, while Ion procedure volume surged 218% to 23,500.
  • 3Instruments and accessories revenue, a key recurring revenue stream, increased 13% to $3.52 billion.
  • 4Systems revenue decreased 1% to $1.68 billion, with da Vinci system placements declining 6% year-over-year, reflecting macroeconomic pressures on hospital capital spending.
  • 5The da Vinci installed base grew 12% to 7,544 systems, and the Ion installed base increased 149% to 321 systems.
  • 6Gross profit margin decreased to 67.4% from 69.3% in 2021, impacted by increased costs and unfavorable foreign currency effects.
  • 7Operating income decreased 13% to $1.58 billion due to increased operating expenses, particularly in R&D and SG&A, to support business growth.

Frequently Asked Questions

Intuitive Surgical's business model revolves around its da Vinci Surgical Systems, Ion endoluminal systems, and related instruments, accessories, and services. Revenue is generated from the initial sale or lease of these systems (capital revenue) and, significantly, from the recurring sale of instruments, accessories, and service contracts used during procedures (recurring revenue). The company aims to expand minimally invasive care by providing physicians and hospitals with advanced robotic technology, comprehensive training, and support services, aligning with the 'quadruple aim' of improving patient outcomes, patient experience, care team satisfaction, and reducing the total cost of care.

Macroeconomic conditions, including inflation, rising interest rates, and supply chain constraints, presented challenges in 2022. These factors impacted hospital capital spending, leading to a 1% decrease in systems revenue and a 6% decline in da Vinci system placements. While recurring revenue from instruments, accessories, and services continued to grow, the overall gross profit margin saw a slight decrease due to increased freight, material costs, and unfavorable foreign currency impacts. The company indicated a softening in its U.S. capital pipeline due to these pressures.

Procedure volume is a critical driver of Intuitive Surgical's recurring revenue and overall business health. The company reported an 18% increase in da Vinci procedures in 2022, demonstrating strong adoption and utilization of its installed base. This growth in procedures directly fuels sales of instruments and accessories, which represent a substantial portion of the company's revenue and profit. The significant increase in Ion system procedures also indicates growing adoption of its diagnostic capabilities.

Intuitive Surgical faces several key risks, including intense competition from existing and emerging robotic surgery companies, reliance on sole and single-source suppliers leading to potential supply chain disruptions, and the complex and evolving regulatory environment for medical devices globally. Furthermore, macroeconomic downturns, changes in healthcare reimbursement policies, potential product liability claims, and the need for continuous innovation to maintain market leadership are significant challenges. The company also highlights risks related to cybersecurity and data privacy.